AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioXcel Therapeutics CEO to participate in virtual fireside chat on Aug 14, 2025.
ByAinvest
Wednesday, Aug 13, 2025 7:04 am ET1min read
BioXcel Therapeutics CEO Vimal Mehta will participate in a virtual fireside chat on August 14, 2025, as part of H.C. Wainwright & Co.'s "HCW@Home" series. The biopharmaceutical company utilizes artificial intelligence to develop transformative medicines in neuroscience, with a focus on the development of medicines in immuno-oncology.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence to develop transformative medicines in neuroscience, has announced that CEO Vimal Mehta, Ph.D., will participate in a virtual fireside chat as part of H.C. Wainwright & Co.'s "HCW@Home" series. The event, scheduled for Thursday, August 14, 2025, at 1:00 p.m. ET, will provide insights into the company's operations and developments.The company, which utilizes artificial intelligence to discover and develop innovative medicines, is focused on the development of medicines in immuno-oncology. Its wholly owned subsidiary, OnkosXcel Therapeutics, is dedicated to the development of medicines in this area. BioXcel Therapeutics employs a drug re-innovation approach, combining existing approved drugs and clinically validated product candidates with big data and proprietary machine learning algorithms to identify new therapeutic indications.
The upcoming fireside chat will offer investors and financial professionals the opportunity to engage with Vimal Mehta and learn more about BioXcel Therapeutics' strategic initiatives and clinical advancements. The company has recently reported its financial results for the second quarter of 2025 and announced the completion of its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. Topline results from this trial are expected in August and are intended to support a potential submission for label expansion of IGALMI® in the at-home setting.
Additionally, BioXcel Therapeutics is exploring the potential applications of BXCL501 in chronic conditions, with recent research published in the journal Frontiers in Pharmacology suggesting the drug's mechanism of action in reducing stress-induced behaviors related to psychiatric disorders. The company is also strengthening its cash position and evaluating CROs for trial initiation in its TRANQUILITY In-Care Phase 3 trial for acute treatment of agitation associated with Alzheimer’s dementia.
Investors and financial professionals are encouraged to register for the virtual fireside chat to gain a deeper understanding of BioXcel Therapeutics' progress and future plans.
References:
[1] https://www.stocktitan.net/news/BTAI/bio-xcel-therapeutics-to-participate-in-the-h-c-wainwright-co-hcw-fixzi4mnp2wv.html
[2] https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-second-quarter-2025-financial
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet